56013-01-5

Basic information

• Product Name: β-CyclogeranyltriphenylphosphoniuM BroMide
• Synonyms: β-CyclogeranyltriphenylphosphoniuM BroMide;Triphenyl[(2,6,6-triMethyl-1-cyclohexen-1-yl)Methyl]phosphoniuM BroMide;2-Cyclogeranyltriphenylphosphonium Bromide
• CAS NO: 56013-01-5
• Molecular Formula: Br*C₂₈H₃₂P
• Molecular Weight: 479.431441
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 56013-01-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: β-CyclogeranyltriphenylphosphoniuM BroMide(CAS DataBase Reference)
• NIST Chemistry Reference: β-CyclogeranyltriphenylphosphoniuM BroMide(56013-01-5)
• EPA Substance Registry System: β-CyclogeranyltriphenylphosphoniuM BroMide(56013-01-5)

Safety Data

• Hazardous Substances Data: 56013-01-5(Hazardous Substances Data)

Usage

Uses

Intermediate in the preparation of Retinoic Acid derivatives and Retinoid analogs.

Upstream product

• 78-70-6 3,7-dimethylocta-1,6-dien-3-ol 
• 472-20-8 β-cyclogeraniol 
• 432-25-7 2,6,6-trimethylcyclohex-1-enecarbaldehyde 
• 59633-88-4 2-(bromomethyl)-1,3,3-trimethylcyclohex-1-ene 
• 603-35-0 triphenylphosphine 
• 6399-81-1 triphenylphosphine hydrobromide 

Downstream Products

• 75859-98-2 (2E,4E)-3-Bromo-5-(2,6,6-trimethyl-cyclohex-1-enyl)-penta-2,4-dienoic acid ethyl ester 
• 77837-62-8 (1E,3E)-1-(4-carboethoxy-3-methylphenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3-butadiene 
• 189271-84-9 2-[(E)-2-(2,6,6-Trimethyl-cyclohex-1-enyl)-vinyl]-furan-3-carboxylic acid ethyl ester 
• 223742-36-7 2-[(E)-2-(2,6,6-Trimethyl-cyclohex-1-enyl)-vinyl]-benzoic acid ethyl ester 
• 77837-56-0 (E)-1-(4-carbethoxyphenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)butadiene 
• 87424-83-7 4-Methyl-6-<(1E,3E)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3-butadien-1-yl>-2H-pyran-2-on 
• 86471-17-2 methyl 6-<(Z)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethen-1-yl>-2-naphthalenecarboxylate 
• 86471-12-7 methyl 6-<(E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethen-1-yl>-2-naphthalenecarboxylate 
• 14538-58-0 3-methyl-5t-(2,6,6-trimethyl-cyclohex-1-enyl)-penta-2t,4-dienoic acid methyl ester 
• 14398-44-8 (2Z,4E)-3-methyl-5-(2',6',6'-trimethylcyclohex-1'-en-1'-yl)-2,4-pentadienoic acid 
• 79-81-2 retinyl palmitate 
• 127-47-9 Retinol acetate 
• 62285-98-7 5-(2,6,6-trimethylcyclohexenyl)-3-methyl-2,4-pentadienyltriphenylphosphonium bromide 
• 53282-28-3 [(2E,4E)-3-methyl-5-(2,6,6-trimethylcyclohex-1-en-1-yl)penta-2,4-dienyl]triphenylphosphonium chloride 

Relevant articles and documents

Preparation method of vitamin A ester intermediate C15 and vitamin A ester

The invention provides a preparation method of a vitamin A ester intermediate C15 and vitamin A ester. The method comprises the following steps: carrying out a halogenation reaction and a cyclizationreaction on 3, 7-dimethyl-3-hydroxy-1, 6-octadiene as an initial raw material, carrying out a substitution reaction on the obtained product and triphenylphosphine or triester phosphite to prepare a corresponding Wittig reagent, carrying out a Wittig reaction on the Wittig reagent and 2-methyl-4-acetoxy-2-butenal, performing acidifying, hydrolyzing and acidifying the obtained product, and carryingout a substitution reaction on the hydrolyzed and acidified product and triphenylphosphine or triester phosphite to prepare C15. The vitamin A ester can be prepared by carrying out a Wittig reaction on the obtained C15 and 2-methyl-4-R3 substituent carbonyloxy-2-butenal. The method has the advantages of single reaction type, easy operation and realization of reaction conditions, safe and environment-friendly operation, simple post-treatment and low cost; and the reaction activity is strong, the reaction selectivity is high, the atom economy is high, and the target product yield and purity arehigh.

STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.